Study Links GLP-1 Drugs to Reduced Risk of Age-Related Macular Degeneration
GLP-1 drugs, including Ozempic, have significantly changed the landscape of healthcare in recent years by providing new treatment options for conditions such as type 2 diabetes and obesity. While these medications are primarily known for their ability to lower blood sugar levels and reduce appetite, ongoing research continues to reveal additional effects of GLP-1 receptor agonists on overall health. A recent study published in the journal Diabetes, Obesity and Metabolism has uncovered a potential new benefit of these drugs: a reduced risk of age-related macular degeneration (AMD), a leading cause of irreversible vision loss in older adults.
The study, led by clinical pharmacology researcher Cheng-Hsien Hung from Chung Shan Medical University in Taiwan, analyzed patient data from more than 157,000 individuals aged 60 and older, all of whom had obesity but did not have diabetes. The cohort was divided into two groups, each consisting of nearly 79,000 patients. One group included those who had started using GLP-1 drugs for weight management, such as liraglutide, semaglutide, or tirzepatide, while the other group comprised individuals using alternative non-GLP-1 medications for weight loss.
Over the follow-up period, patients using GLP-1 drugs exhibited a significantly lower incidence of AMD compared to those using other weight-loss medications. Specifically, the use of GLP-1 drugs was associated with an estimated 18% lower risk of developing AMD, a figure that increased to 30% when considering unspecified cases of AMD. However, no significant association was found for the wet form of AMD, while a trend toward reduced risk of dry AMD was observed, though it did not reach statistical significance.
Previous studies have hinted at a similar protective effect of GLP-1 drugs against AMD, particularly in patients with type 2 diabetes. The current research aimed to focus on individuals without diabetes to eliminate potential confounding factors related to glycemic control. The researchers speculate that GLP-1 drugs may exert a neuroprotective effect by reducing inflammation in the retina, potentially through the suppression of an inflammasome known as NLRP3. Alternatively, it is possible that the greater weight loss achieved by patients using GLP-1 drugs compared to those on other treatments could contribute to the observed reduction in AMD risk.
The study authors note that weight loss itself can lower systemic inflammation and oxidative stress, which may independently reduce the risk of AMD. They emphasize the importance of distinguishing whether the protective effect is primarily due to the neuroprotective properties of GLP-1 drugs or simply a consequence of weight loss. This distinction is crucial and requires further investigation through prospective mechanistic studies.
The findings of this study are particularly relevant given that previous research indicated an increase in AMD risk of 2% for every 1 kg/m2 increase in body mass index among overweight and obese individuals. However, the authors caution that the median follow-up period for the study was relatively short, with only one year for GLP-1 users and 2.5 years for the comparison group. This limitation means that the long-term effects of GLP-1 drugs on AMD risk remain uncertain.
In conclusion, while the study presents promising findings regarding the potential benefits of GLP-1 drugs in reducing the risk of AMD, further research is necessary to clarify the mechanisms involved and to validate these results across different populations and longer follow-up periods. The implications of these findings could significantly impact how GLP-1 drugs are viewed in the context of metabolic health and eye health.




